Latest News

September 8, 2022

Press Release: ECOG-ACRIN completes the first randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

August 16, 2022

The August 2022 News from ECOG-ACRIN blog is now available

August 10, 2022

President Biden announces his intent to appoint Dr. Monica Bertagnolli as the next NCI director

August 9, 2022

Early-career investigators: Submit an abstract for the 2022 Young Investigator Symposium by Wednesday, 9/7

July 21, 2022

Group co-chairs Peter O’Dwyer and Mitch Schnall commend the selection of Monica Bertagnolli as the next NCI director

July 15, 2022

Ongoing Smoke Free Support Study 2.0 featured in BioMed Central’s Public Health Journal

July 14, 2022

Media Advisory: Blood publishes long-term outcomes of patients with CLL in the practice-changing E1912 trial

July 2, 2022

What is ECOG-ACRIN EA2142? And why should you care?

June 28, 2022

The Summer 2022 advocacy blog, Considering Clinical Trials, is now available


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
43

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group